PRQR
PRQR
NASDAQ · Biotechnology

Proqr Therapeutics Nv

$1.86
+0.03 (+1.64%)
As of Jun 30, 10:28 PM ET ·
Financial Highlights (FY 2026)
Revenue
16.73M
Net Income
-43,162,398
Gross Margin
Profit Margin
-258.1%
Rev Growth
+50.5%
D/E Ratio
0.32
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 46.9% 46.9%
Operating Margin -265.8% -239.2% 5.6% 5.8%
Profit Margin -258.1% -245.2% 4.3% 4.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 16.73M 11.12M 53.79M 56.60M
Gross Profit 25.23M 26.55M
Operating Income -44,452,961 -26,592,000 2.99M 3.30M
Net Income -43,162,398 -25,819,978 2.31M 2.33M
Gross Margin 46.9% 46.9%
Operating Margin -265.8% -239.2% 5.6% 5.8%
Profit Margin -258.1% -245.2% 4.3% 4.1%
Rev Growth +50.5% +50.5% +4.8% +15.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 20.14M 20.14M 17.98M 18.29M
Total Equity 62.30M 62.30M 107.54M 109.94M
D/E Ratio 0.32 0.32 0.17 0.17
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -42,052,353 -26,553,496 4.13M 4.65M
Free Cash Flow 1.88M 2.75M